Preprint Concept Paper Version 1 Preserved in Portico This version is not peer-reviewed

Hydroxychloroquine for the Treatment of COVID-19: Evidence, Possible Mode of Action and Industrial Supply of the Drug

Version 1 : Received: 20 April 2020 / Approved: 21 April 2020 / Online: 21 April 2020 (08:26:31 CEST)

A peer-reviewed article of this Preprint also exists.

Journal reference: Medicine Research 2020
DOI: 10.21127/yaoyimr20200014


Hydroxychloroquine, a known antiviral metabolite of chloroquine, is increasingly used along with antibiotic azithromycin for the treatment of COVID-19 infection. In about one month India, the world’s largest manufacturer, delivered hydroxychloroquine for treating COVID-19 to over 50 countries. The therapy is being used across the world both for patients staying at home at the early phase of symptoms, as well as for patients hospitalized. We summarize achievements as of late April 2020, review possible modes of action and suggest avenues for the quick scale-up of production of hydroxychloroquine.


hydroxychloroquine; COVID-19; immunomodulator; cytokine storm; flow chemistry



Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.